Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers

Stutterheim J., Gerritsen A., Zappeij-Kannegieter L., YALÇIN B. , Dee R., van Noesel M. M. , ...Daha Fazla

CLINICAL CHEMISTRY, cilt.55, ss.1316-1326, 2009 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 55 Konu: 7
  • Basım Tarihi: 2009
  • Doi Numarası: 10.1373/clinchem.2008.117945
  • Sayfa Sayıları: ss.1316-1326


BACKGROUND: PCR-based detection of minimal residual disease (MRD) in neuroblastoma (NB) patients can be used for initial staging and monitoring therapy response in bone marrow (BM) and peripheral blood (PB). PHOX2B has been identified as a sensitive and specific MRD marker; however, its expression varies between tumors. Therefore, a panel of markers could increase sensitivity.